{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:23:53Z","timestamp":1761845033291},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.2169\/internalmedicine.2755-19","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T22:03:32Z","timestamp":1561586612000},"page":"3125-3128","source":"Crossref","is-referenced-by-count":5,"title":["Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes"],"prefix":"10.2169","volume":"58","author":[{"given":"Tamami","family":"Oshige","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Kawano","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ohki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehisa","family":"Tsuruta","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Tokubuchi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Asakura Medical Association Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ashida","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 12: 1048-1057, 2010."},{"key":"2","unstructured":"2. Defronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34: 789-794, 2011."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 44: 1349-1355, 1995.","DOI":"10.1016\/0026-0495(95)90041-1"},{"key":"4","unstructured":"4. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: 214-223, 1979."},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.","DOI":"10.1007\/BF00280883"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Barnett AH, Chapman C, Gailer K, Hayter CJ. Effect of bromocriptine on maturity onset diabetes. Postgrad Med J 56: 11-14, 1980.","DOI":"10.1136\/pgmj.56.651.11"},{"key":"7","unstructured":"7. Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14: 335-340, 2012."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Adele B, Zahra K, Ezzatossadat D, Ozra A, Shahram A. Effects of cabergoline on blood glucose levels in type 2 diabetic patients. A double-blind controlled clinical trial. Medicine (Baltimore) 95: e4818, 2016.","DOI":"10.1097\/MD.0000000000004818"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cincotta AH. Hypothalamic role in the insulin resistance syndrome. In: Insulin resistance syndrome. Hansen B, Shaffrir E, Eds. Taylor and Francis, London, 2002: 271-312.","DOI":"10.3109\/9780203217412-19"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol 1: 2, 2015.","DOI":"10.1186\/s40842-015-0001-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mejia-Rodriguez O, Herrera-Abarca JE, Ceballos-Reyes G, et al. Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. Biomed Res Int 2013: 104059, 2013.","DOI":"10.1155\/2013\/104059"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33: 1503-1508, 2010.","DOI":"10.2337\/dc09-2009"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_2755-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T03:42:48Z","timestamp":1572666168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_2755-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":12,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2755-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}